Sort by
Refine Your Search
-
. To achieve our objectives, we will use cutting-edge technologies (CITE-seq, RNA-seq, Ribo-seq) and combine analysis in readily available relevant cellular models of cancer-experienced T cells, syngeneic mouse
-
to improve patients’ prognosis. Novel niche-hematopoietic crosstalk-induced dependencies will be unraveled using omic approaches combined to high-throughput functional screening methods. Pre-leukemic in vivo
Searches related to combinators
Enter an email to receive alerts for combinators positions